Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Harrow, Inc.

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
From Harrow, Inc.
Via Business Wire
Tickers HROW
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Relaunches TRIESENCE®
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Announces Nashville Expansion
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow to Present at Three Investor Conferences in September in New York
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Announces Second Quarter 2024 Financial Results
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow to Attend 2024 ASRS Annual Meeting
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Provides TRIESENCE® Relaunch Update
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow to Present at Two Investor Conferences in May
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Announces First Quarter 2024 Financial Results
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Announces New Appointments to its Board of Directors
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Partners with Leading Healthcare Market Access Technology Platforms
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Completes Transfer of the TRIESENCE® New Drug Application
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow to Present at Two Investor Conferences in November
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Announces Third Quarter 2023 Financial Results
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
From Harrow, Inc.
Via Business Wire
Tickers HROW
Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.
From Harrow, Inc.
Via Business Wire
Tickers HROW
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.